Evidence map›Paper›PMID 38659814›Full record

ArticleResearch square2024

B cell immunofocusing and repriming in two HIV-1 Env immunization regimens.

Jenna M DeLuca, Maria Blasi, Shalini Jha, Xiaoying Shen, Justin Pollara, Melissa Kerkau, Mansi Purwar, Diane G Carnathan, Donatella Negri, Andrea Cara and 9 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Jenna M DeLucaTranslational Immunobiology Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-6390-8436
Maria BlasiDuke Human Vaccine Institute, Duke University, Durham, NC, USA.ORCID 0000-0002-7091-0312
Shalini JhaDuke Human Vaccine Institute, Duke University, Durham, NC, USA.
Xiaoying ShenDuke Human Vaccine Institute, Duke University, Durham, NC, USA.
Justin PollaraDuke Human Vaccine Institute, Duke University, Durham, NC, USA.
Melissa KerkauDuke Human Vaccine Institute, Duke University, Durham, NC, USA.
Mansi PurwarWistar Institute, Philadelphia, PA, USA.
Diane G CarnathanEmory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Donatella NegriDuke Human Vaccine Institute, Duke University, Durham, NC, USA.
Andrea CaraDuke Human Vaccine Institute, Duke University, Durham, NC, USA.ORCID 0000-0003-4967-1895
Kurt WollenbergBioinformatics & Computational Biosciences Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Kevin O SaundersDuke Human Vaccine Institute, Duke University, Durham, NC, USA.ORCID 0000-0001-7399-7954
Shan LuUniversity of Massachusetts Medical School, Worcester, MA, USA.
Guido SilvestriEmory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
David B WeinerWistar Institute, Philadelphia, PA, USA.
Mary E KlotmanDuke Human Vaccine Institute, Duke University, Durham, NC, USA.ORCID 0000-0002-7084-0406
Guido FerrariDuke Human Vaccine Institute, Duke University, Durham, NC, USA.ORCID 0000-0001-7747-3349
M Anthony MoodyDuke Human Vaccine Institute, Duke University, Durham, NC, USA.
Mattia BonsignoriTranslational Immunobiology Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0003-2973-2101
Duke University · USThe Wistar Institute · USNational Institute of Allergy and Infectious Diseases · USEmory University · USUniversity of Massachusetts Chan Medical School · US

Funding

Synthetic DNA & Novel Env Vaccine for HIVU19AI109646 · NIAID · WISTAR INSTITUTE · PI SARDESAI, NIRANJAN Y · 2015 to 2019
$16.7M
Safety and Durability of Integrase Defective Lentiviral vector for an HIV VaccineP01AI110485 · NIAID · DUKE UNIVERSITY · PI KLOTMAN, MARY E. · 2015 to 2019
$9.0M
NIAID NIH HHS P01 AI110485NIAID NIH HHS U19 AI109646
6 · The paper itself

Abstract

Diverse and rapidly mutating viruses pose challenges to immunogen and vaccine design. In this study, we evaluated the ability of memory B-cells obtained from two independent NHP trials to cross-react with individual HIV-1 vaccine components of two different multivalent immunization strategies. We demonstrated that while an HIV-1 Env multiclade, multivalent immunization regimen resulted in a dominant memory B-cell response that converged toward shared epitopes, in a sequential immunization with clonally-related non-stabilized gp140 HIV-1 Envs followed by SOSIP-stabilized gp140 trimers, the change in immunogen format resulted in repriming of the B-cell response.

Identifiers

PMID38659814
PMCPMC11042408
OpenAlexW4394576205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.